Fagan Associates, Inc. Regeneron Pharmaceuticals, Inc. Transaction History

Fagan Associates, Inc.

$526 Million
Q1 2024

A detailed history of Fagan Associates, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Fagan Associates, Inc. holds 8,944 shares of REGN stock, worth $9.58 Million. This represents 1.64% of its overall portfolio holdings.

Number of Shares

8,944

Previous 8,728 2.47%

Holding current value

$9.58 Million

Previous $7.67 Million 12.3%

% of portfolio

1.64%

Previous 1.67%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$902.69 - $993.35 $194,981 - $214,563	216 Added 2.47%	8,944 $8.61 Million
Q4 2023 Feb 07, 2024	BUY	$775.18 - $881.7 $70,541 - $80,234	91 Added 1.05%	8,728 $7.67 Million
Q3 2023 Oct 31, 2023	BUY	$692.45 - $844.37 $245,127 - $298,906	354 Added 4.27%	8,637 $7.11 Million
Q2 2023 Aug 08, 2023	BUY	$700.03 - $830.35 $101,504 - $120,400	145 Added 1.78%	8,283 $5.95 Million
Q1 2023 May 03, 2023	BUY	$680.49 - $826.97 $121,127 - $147,200	178 Added 2.24%	8,138 $6.69 Million

Q4 2022 Jan 25, 2023	SELL	$705.89 - $766.39 $92,471 - $100,397	-131 Reduced 1.62%	7,960 $0
Q3 2022 Nov 01, 2022	SELL	$573.97 - $724.32 $22,958 - $28,972	-40 Reduced 0.49%	8,091 $5.57 Million
Q2 2022 Aug 03, 2022	SELL	$548.35 - $738.84 $1,645 - $2,216	-3 Reduced 0.04%	8,131 $4.81 Million
Q1 2022 May 06, 2022	BUY	$595.12 - $698.43 $114,263 - $134,098	192 Added 2.42%	8,134 $5.68 Million
Q4 2021 Feb 08, 2022	BUY	$543.48 - $670.97 $122,283 - $150,968	225 Added 2.92%	7,942 $5.02 Million
Q3 2021 Nov 09, 2021	BUY	$574.03 - $680.96 $2,296 - $2,723	4 Added 0.05%	7,717 $4.67 Million
Q2 2021 Aug 06, 2021	BUY	$472.8 - $558.54 $115,363 - $136,283	244 Added 3.27%	7,713 $4.31 Million
Q1 2021 May 06, 2021	BUY	$446.73 - $548.2 $313,604 - $384,836	702 Added 10.37%	7,469 $3.53 Million
Q4 2020 Feb 08, 2021	BUY	$478.3 - $607.98 $232,453 - $295,478	486 Added 7.74%	6,767 $3.27 Million
Q3 2020 Nov 02, 2020	BUY	$544.75 - $658.21 $314,865 - $380,445	578 Added 10.14%	6,281 $3.52 Million
Q2 2020 Aug 05, 2020	SELL	$493.32 - $643.92 $20,226 - $26,400	-41 Reduced 0.71%	5,703 $3.56 Million
Q1 2020 May 05, 2020	BUY	$336.18 - $494.43 $1.74 Million - $2.56 Million	5,187 Added 931.24%	5,744 $2.81 Million
Q4 2019 Feb 07, 2020	BUY	$274.13 - $376.51 $152,690 - $209,716	557 New	557 $209,000
Q2 2019 Jul 12, 2019	SELL	$299.6 - $414.82 $164,780 - $228,151	-550 Closed	0 $0
Q3 2018 Nov 06, 2018	SELL	$351.14 - $408.51 $19,312 - $22,468	-55 Reduced 9.09%	550 $222,000
Q4 2017 Feb 09, 2018	SELL	$358.63 - $469.95 $972,963 - $1.27 Million	-2,713 Reduced 81.77%	605 $227,000
Q3 2017 Nov 13, 2017	BUY	$431.38 - $504.0 $87,570 - $102,312	203 Added 6.52%	3,318 $1.48 Million
Q2 2017 Aug 07, 2017	BUY	N/A	3,115	3,115 $1.53 Million

Others Institutions Holding REGN

# of Institutions

1,430

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $115B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fagan Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Fagan Associates, Inc. with notifications on news.

Account

Fagan Associates, Inc. Regeneron Pharmaceuticals, Inc. Transaction History